GALLIUM GA 68 GOZETOTIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GALLIUM GA 68 GOZETOTIDE (GALLIUM GA 68 GOZETOTIDE).
Gallium Ga 68 gozetotide is a radioactive diagnostic agent that binds to prostate-specific membrane antigen (PSMA), a transmembrane protein overexpressed on prostate cancer cells. After binding, the gallium-68 isotope emits positrons for PET imaging.
| Metabolism | Gallium Ga 68 gozetotide undergoes minimal metabolism; the primary route of elimination is renal excretion of the intact drug. |
| Excretion | Renal excretion: 100% of administered dose eliminated unchanged in urine within 24 hours. No biliary or fecal elimination significant. |
| Half-life | Terminal elimination half-life: 1.5 hours (range 1.2–1.8 hours) based on decay of Gallium-68 and renal clearance. Clinically, this allows imaging up to 2–3 hours post-injection. |
| Protein binding | Approximately 10–15% bound to plasma proteins (albumin and transferrin). |
| Volume of Distribution | Apparent volume of distribution: 0.4–0.6 L/kg, indicating distribution primarily in extracellular fluid and tissues expressing somatostatin receptors. |
| Bioavailability | Not applicable (administered only as intravenous injection; no oral bioavailability). |
| Onset of Action | Intravenous: Target binding and positron emission occur immediately; optimal imaging time is 40–90 minutes post-injection. |
| Duration of Action | Duration of diagnostic utility: Up to 2–3 hours post-injection due to radioactive decay (physical half-life 68 minutes) and biological clearance. Imaging performed within this window. |
148-222 MBq (4-6 mCi) intravenously as a single dose for PET imaging.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for any degree of renal impairment; elimination is via decay and physical excretion, with minimal renal clearance. |
| Liver impairment | No dose adjustment required for hepatic impairment; metabolism is negligible. |
| Pediatric use | Weight-based: 2 MBq/kg (0.054 mCi/kg) intravenously, minimum 25 MBq (0.7 mCi), maximum 222 MBq (6 mCi). |
| Geriatric use | No specific dose adjustment; use standard adult dose with consideration of renal function, though no adjustment is needed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GALLIUM GA 68 GOZETOTIDE (GALLIUM GA 68 GOZETOTIDE).
| Breastfeeding | Gallium Ga 68 gozetotide is excreted in human milk, but specific data for this agent are lacking. Advise temporary cessation of breastfeeding after administration. The M/P ratio is unknown. To minimize infant exposure, express and discard breast milk for at least 4 half-lives (approximately 48 hours, given 68-minute half-life) after injection. |
| Teratogenic Risk | Gallium Ga 68 gozetotide is a radiopharmaceutical; radiation exposure poses a risk to the fetus. In pregnancy, it is contraindicated unless the potential benefit justifies the risk. First trimester: Highest risk of teratogenicity (malformations, growth retardation, CNS damage). Second and third trimesters: Risk of carcinogenesis and genetic defects. Fetal radiation dose should be minimized; use only if diagnostic information cannot be obtained by other means. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to gallium Ga 68 gozetotide or any of its components"]
| Precautions | ["Risk of misdiagnosis due to false positive or false negative results","Radiation exposure to patients and healthcare personnel","Hypersensitivity reactions including anaphylaxis have been reported"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs during and after administration. No specific fetal monitoring is required, but consider fetal radiation dose assessment if exposure occurs. Ensure patient is not pregnant before administration; perform pregnancy test if indicated. |
| Fertility Effects | No specific fertility effects reported for Gallium Ga 68 gozetotide. As a radiopharmaceutical, radiation may affect ovaries or testes; theoretical risk of genetic damage. Long-term effects on fertility unknown. |